Table 3. Antibody response determined by using NT assays after vaccination with intradermal and virosomal/intramuscular vaccine.

	Vaccine route of administration and adjuvant		p-value
	Intradermal	Virosomal Intramuscular
Geometric Mean Titer 1 mo post-vaccination
A(H1N1) vaccine strain	28 (17–44)	19 (12–31)	NS
A/Genoa/1/11(H1N1)	80 (44–147)	44 (23–84)	NS
A/Genoa/6/11(H1N1)	90 (48–169)	37 (19–69)	< 0.05
A/Genoa/24/11(H1N1)	49 (28–86)	20 (11–37)	< 0.05
A/Genoa/89/11(H1N1)	35 (20–61)	20 (10–38)	NS
Mean Fold Increase 1 mo post-vaccination
A(H1N1) vaccine strain	3.5 (2–6)	2.4 (1.3–4.3)
A/Genoa/1/11(H1N1)	4.9 (2.3–10.5)	4 (1.9–8.9)
A/Genoa/6/11(H1N1)	5.8 (2.8–12)	3.9 (1.8–8.1)
A/Genoa/24/11(H1N1)	3.7 (1.9–7.1)	2.5 (1.2–5)
A/Genoa/89/11(H1N1)	4.2 (2.3–7.9)	2.5 (1.3–5.2)
Seroconversion rate 1 mo post-vaccination (%, 95% C.I.)
A(H1N1) vaccine strain	54 (35–72)	44 (26–63)	NS
A/Genoa/1/11(H1N1)	54 (35–72)	48 (30–67)	NS
A/Genoa/6/11(H1N1)	58 (39–76)	30 (16–51)	NS
A/Genoa/24/11(H1N1)	58 (39–76)	39 (22–59)	NS
A/Genoa/89/11(H1N1)	50 (31–69)	26 (13–47)	NS
Titer ≥ 40 rate 1 mo post-vaccination (%, 95% C.I.)
A(H1N1) vaccine strain	58 (39–76)	48 (29–67)	NS
A/Genoa/1/11(H1N1)	75 (55–88)	65 (45–81)	NS
A/Genoa/6/11(H1N1)	75 (55–88)	44 (26–63)	< 0.05
A/Genoa/24/11(H1N1)	79 (60–91)	39 (22–59)	< 0.05
A/Genoa/89/11(H1N1)	54 (35–72)	30 (16–51)	NS
Geometric Mean Titer 3 mo post-vaccination
A(H1N1) vaccine strain	22 (13–37)	13 (8–20)	NS
A/Genoa/1/11(H1N1)	46 (25–85)	27 (15–48)	NS
A/Genoa/6/11(H1N1)	57 (30–105)	22 (12–37)	< 0.05
A/Genoa/24/11(H1N1)	51 (27–95)	14 (10–27)	< 0.05
A/Genoa/89/11(H1N1)	25 (14–43)	11 (7–19)	< 0.05
Titer ≥ 40 rate 3 mo post-vaccination (%, 95% C.I.)
A(H1N1) vaccine strain	55 (34–74)	32 (15–54)	NS
A/Genoa/1/11(H1N1)	60 (39–78)	42 (23–64)	NS
A/Genoa/6/11(H1N1)	65 (43–82)	37 (19–59)	NS
A/Genoa/24/11(H1N1)	75 (53–89)	21 (9–43)	< 0.05
A/Genoa/89/11(H1N1)	45 (26–66)	21 (9–43)	NS